Newron Pharmaceuticals S.p.A. is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system.
Quote | Newron Pharms Spa Ord (OTCMKTS:NWPHF)
Last: | $2.80 |
---|---|
Change Percent: | 0.0% |
Open: | $2.8 |
Close: | $2.80 |
High: | $2.8 |
Low: | $2.8 |
Volume: | 2,000 |
Last Trade Date Time: | 06/08/2021 04:41:54 am |
News | Newron Pharms Spa Ord (OTCMKTS:NWPHF)
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...
Ad hoc announcement pursuant to Art. 53 LR Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically important reducti...
Message Board Posts | Newron Pharms Spa Ord (OTCMKTS:NWPHF)
Subject | By | Source | When |
---|---|---|---|
No posts yet. |
News, Short Squeeze, Breakout and More Instantly...
Newron Pharms Spa Ord Company Name:
NWPHF Stock Symbol:
OTCMKTS Market:
Ad hoc announcement pursuant to Art. 53 LR EIB agrees to extend repayment dates of tranches one to three of its loan to the Company until end of 2025 and into 2026, after potentially significant pipeline milestones Amended agreement envisages EIB will now receive certain performan...
Ad hoc announcement pursuant to Art. 53 LR Treatment with evenamide demonstrated significant, clinically important, progressive, sustained and long-lasting improvement on PANSS total, CGI-S and Level of Functioning (LOF) More than 70% of patients experienced clinically important reducti...
Ad hoc announcement pursuant to Art. 53 LR 290 patients participate at study centers in Europe, Asia and Latin America Results from the study are expected in March 2024 Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutica...